160 related articles for article (PubMed ID: 34619755)
1. Interlaboratory Analytical Validation of a Next-Generation Sequencing Strategy for Clonotypic Assessment and Minimal Residual Disease Monitoring in Multiple Myeloma.
Medina A; Jiménez C; Puig N; Sarasquete ME; Flores-Montero J; García-Álvarez M; Prieto-Conde I; Chillón C; Alcoceba M; González-Calle V; Gutiérrez NC; Jacobsen A; Vigil E; Hutt K; Huang Y; Orfao A; González M; Miller J; García-Sanz R
Arch Pathol Lab Med; 2022 Jul; 146(7):862-871. PubMed ID: 34619755
[TBL] [Abstract][Full Text] [Related]
2. Upgraded Standardized Minimal Residual Disease Detection by Next-Generation Sequencing in Multiple Myeloma.
Yao Q; Bai Y; Orfao A; Kumar S; Chim CS
J Mol Diagn; 2020 May; 22(5):679-684. PubMed ID: 32151713
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of next-generation sequencing versus next-generation flow cytometry for minimal-residual-disease detection in Chinese patients with multiple myeloma.
Zhou M; Chen Y; Gong Y; Zhu M; Cen J; Pan J; Yan L; Shang J; Jin S; Shi X; Yao W; Yan S; Wu D; Chen S; Fu C; Yao L
Discov Oncol; 2024 Mar; 15(1):78. PubMed ID: 38502423
[TBL] [Abstract][Full Text] [Related]
4. Ig Gene Clonality Analysis Using Next-Generation Sequencing for Improved Minimal Residual Disease Detection with Significant Prognostic Value in Multiple Myeloma Patients.
Ha J; Lee H; Shin S; Cho H; Chung H; Jang JE; Kim SJ; Cheong JW; Lee ST; Kim JS; Choi JR
J Mol Diagn; 2022 Jan; 24(1):48-56. PubMed ID: 34656761
[TBL] [Abstract][Full Text] [Related]
5. Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myeloma.
Medina A; Puig N; Flores-Montero J; Jimenez C; Sarasquete ME; Garcia-Alvarez M; Prieto-Conde I; Chillon C; Alcoceba M; Gutierrez NC; Oriol A; Rosinol L; Bladè J; Gironella M; Hernandez MT; Gonzalez-Calle V; Cedena MT; Paiva B; San-Miguel JF; Lahuerta JJ; Mateos MV; Martinez-Lopez J; Orfao A; Gonzalez M; Garcia-Sanz R
Blood Cancer J; 2020 Oct; 10(10):108. PubMed ID: 33127891
[TBL] [Abstract][Full Text] [Related]
6. Routine Evaluation of Minimal Residual Disease in Myeloma Using Next-Generation Sequencing Clonality Testing: Feasibility, Challenges, and Direct Comparison with High-Sensitivity Flow Cytometry.
Ho C; Syed M; Roshal M; Petrova-Drus K; Moung C; Yao J; Quesada AE; Benhamida J; Vanderbilt C; Liu Y; Zhu M; Yu W; Maciag L; Wang M; Ma Y; Gao Q; Rustad EH; Hultcrantz M; Diamond BT; Zheng-Lin B; Huang Y; Hutt K; Miller JE; Dogan A; Nafa K; Landgren O; Arcila ME
J Mol Diagn; 2021 Feb; 23(2):181-199. PubMed ID: 33217553
[TBL] [Abstract][Full Text] [Related]
7. Comparison of Measurable Residual Disease in Pediatric B-Lymphoblastic Leukemia Using Multiparametric Flow Cytometry and Next-Generation Sequencing.
Hwang SM; Oh I; Kwon SR; Lee JS; Seong MW
Ann Lab Med; 2024 Jul; 44(4):354-358. PubMed ID: 38237930
[TBL] [Abstract][Full Text] [Related]
8. Capture Rate of V(D)J Sequencing for Minimal Residual Disease Detection in Multiple Myeloma.
Hultcrantz M; Rustad EH; Yellapantula V; Jacob A; Akhlaghi T; Korde N; Mailankody S; Lesokhin AM; Hassoun H; Smith EL; Lahoud OB; Landau HJ; Shah GL; Scordo M; Chung DJ; Giralt S; Papaemmanuil E; Landgren O
Clin Cancer Res; 2022 May; 28(10):2160-2166. PubMed ID: 35553646
[TBL] [Abstract][Full Text] [Related]
9. LymphoTrack Is Equally Sensitive as PCR GeneScan and Sanger Sequencing for Detection of Clonal Rearrangements in ALL Patients.
Paulsen K; Marincevic M; Cavelier L; Hollander P; Amini RM
Diagnostics (Basel); 2022 Jun; 12(6):. PubMed ID: 35741199
[TBL] [Abstract][Full Text] [Related]
10. Quantification of Measurable Residual Disease Detection by Next-Generation Sequencing-Based Clonality Testing in B-Cell and Plasma Cell Neoplasms.
Liu Y; Ho C; Yu W; Huang Y; Miller J; Gao Q; Syed M; Ma Y; Wang M; Maciag L; Petrova-Drus K; Zhu M; Yao J; Vanderbilt C; Durham B; Benhamida J; Ewalt MD; Dogan A; Roshal M; Nafa K; Arcila ME
J Mol Diagn; 2024 Mar; 26(3):168-178. PubMed ID: 38103591
[TBL] [Abstract][Full Text] [Related]
11. Minimal residual disease detection by next-generation sequencing in multiple myeloma: Promise and challenges for response-adapted therapy.
Ferla V; Antonini E; Perini T; Farina F; Masottini S; Malato S; Marktel S; Lupo Stanghellini MT; Tresoldi C; Ciceri F; Marcatti M
Front Oncol; 2022; 12():932852. PubMed ID: 36052251
[TBL] [Abstract][Full Text] [Related]
12. Multiple Myeloma Minimal Residual Disease Detection: Targeted Mass Spectrometry in Blood vs Next-Generation Sequencing in Bone Marrow.
Langerhorst P; Noori S; Zajec M; De Rijke YB; Gloerich J; van Gool AJ; Caillon H; Joosten I; Luider TM; Corre J; VanDuijn MM; Dejoie T; Jacobs JFM
Clin Chem; 2021 Nov; 67(12):1689-1698. PubMed ID: 34643690
[TBL] [Abstract][Full Text] [Related]
13. Validation of a PCR-Based Next-Generation Sequencing Approach for the Detection and Quantification of Minimal Residual Disease in Acute Lymphoblastic Leukemia and Multiple Myeloma Using gBlocks as Calibrators.
Van der Straeten J; De Brouwer W; Kabongo E; Dresse MF; Fostier K; Schots R; Van Riet I; Bakkus M
J Mol Diagn; 2021 May; 23(5):599-611. PubMed ID: 33549860
[TBL] [Abstract][Full Text] [Related]
14. Analytical evaluation of the clonoSEQ Assay for establishing measurable (minimal) residual disease in acute lymphoblastic leukemia, chronic lymphocytic leukemia, and multiple myeloma.
Ching T; Duncan ME; Newman-Eerkes T; McWhorter MME; Tracy JM; Steen MS; Brown RP; Venkatasubbarao S; Akers NK; Vignali M; Moorhead ME; Watson D; Emerson RO; Mann TP; Cimler BM; Swatkowski PL; Kirsch IR; Sang C; Robins HS; Howie B; Sherwood A
BMC Cancer; 2020 Jun; 20(1):612. PubMed ID: 32605647
[TBL] [Abstract][Full Text] [Related]
15. Next-generation sequencing and real-time quantitative PCR for minimal residual disease detection in B-cell disorders.
Ladetto M; Brüggemann M; Monitillo L; Ferrero S; Pepin F; Drandi D; Barbero D; Palumbo A; Passera R; Boccadoro M; Ritgen M; Gökbuget N; Zheng J; Carlton V; Trautmann H; Faham M; Pott C
Leukemia; 2014 Jun; 28(6):1299-307. PubMed ID: 24342950
[TBL] [Abstract][Full Text] [Related]
16. Best practices for the assessment of measurable residual disease (MRD) in multiple myeloma.
Bal S; Costa LJ
Clin Adv Hematol Oncol; 2020 Jan; 18 Suppl 1(1):1-20. PubMed ID: 33843859
[TBL] [Abstract][Full Text] [Related]
17. Real-world data on prognostic value of measurable residual disease assessment by fragment analysis or next-generation sequencing in multiple myeloma.
Cho H; Shin S; Chung H; Jang JE; Kim YR; Cheong JW; Min YH; Lee ST; Choi JR; Kim JS
Br J Haematol; 2022 Aug; 198(3):503-514. PubMed ID: 35505579
[TBL] [Abstract][Full Text] [Related]
18. Reproducibility of low-level residual myeloma immunoglobulin detection using ultra-deep sequencing.
Cédile O; Hansen MH; Dahlmann SK; Kristensen TK; Abildgaard N; Nyvold CG
Exp Hematol; 2023; 119-120():14-20. PubMed ID: 36708872
[TBL] [Abstract][Full Text] [Related]
19. Baseline identification of clonal V(D)J sequences for DNA-based minimal residual disease detection in multiple myeloma.
Rustad EH; Hultcrantz M; Yellapantula VD; Akhlaghi T; Ho C; Arcila ME; Roshal M; Patel A; Chen D; Devlin SM; Jacobsen A; Huang Y; Miller JE; Papaemmanuil E; Landgren O
PLoS One; 2019; 14(3):e0211600. PubMed ID: 30901326
[TBL] [Abstract][Full Text] [Related]
20. Standardized Minimal Residual Disease Detection by Next-Generation Sequencing in Multiple Myeloma.
Yao Q; Bai Y; Orfao A; Chim CS
Front Oncol; 2019; 9():449. PubMed ID: 31245284
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
